Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiotensin II inhibits cortical cholinergic function: implications for cognition.

J M Barnes1, N M Barnes, B Costall

  • 1Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, England.

Journal of Cardiovascular Pharmacology
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical Challenges in Clinical Research During the COVID-19 Pandemic.

Journal of bioethical inquiry·2020
Same author

Capture-recapture to estimate completeness of tuberculosis surveillance in two communities in South Africa.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2011
Same author

Accuracy and completeness of recording of confirmed tuberculosis in two South African communities.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2011
Same author

Traumatic oedema of larynx.

British dental journal·2010
Same author

Behavioural characterization of neuroleptic properties in the rodent.

Proceedings of the Royal Society of Medicine·2010
Same author

The Rationale of Complete Immobilization in Treatment of Infected Wounds.

British medical journal·2010
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Angiotensin II (AT II) inhibits acetylcholine release in rat and human brain tissue. Blocking AT II receptors or ACE may enhance cognitive function by removing this inhibition.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • The renin-angiotensin system plays a role in central nervous system function.
  • Angiotensin II (AT II) is a key peptide in this system, with known effects on blood pressure and fluid balance.
  • Its role in modulating neurotransmitter release, particularly acetylcholine, in brain regions relevant to cognition is less understood.

Purpose of the Study:

  • To investigate the effect of Angiotensin II (AT II) on acetylcholine release in rat and human brain tissue.
  • To determine if AT II receptor antagonists can block these effects.
  • To explore the presence and function of the angiotensin system components in human temporal cortex.

Main Methods:

  • Measurement of potassium-stimulated [3H]acetylcholine ([3H]Ach) release from rat entorhinal cortex and human temporal cortex slices.

Related Experiment Videos

  • Application of varying concentrations of AT II and specific AT II receptor antagonists.
  • Assay for angiotensin-converting enzyme (ACE) activity and AT II recognition sites in human temporal cortex.

    • Main Results:

    • AT II significantly inhibited [3H]Ach release in a concentration-dependent manner in rat tissue and at a single concentration in human tissue.
    • The inhibitory effects of AT II were antagonized by a specific AT II receptor antagonist in both rat and human tissues.
    • ACE activity and AT II recognition sites were confirmed in human temporal cortex tissue.

    Conclusions:

    • Angiotensin II acts as an inhibitory modulator of cholinergic neurotransmission in the rat and human brain.
    • The findings support the hypothesis that ACE inhibitors may enhance cognitive function by reducing AT II formation and its inhibitory effects on acetylcholine release.